MADISON, Wis., Sept. 11, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company will host a discussion with analysts and investors on Monday, September 29, 2025, in conjunction with the American Society of Radiation Oncology (ASTRO) Annual Meeting in San Francisco, California. The event will take place in person at the ASTRO meeting and on a virtual platform, with presentations beginning at 1:30 pm PT (4:30 pm ET).
Analysts participating in the event will have a unique opportunity to hear first-hand from global thought leaders who will share their perspectives on the role of adaptive radiotherapy in radiation medicine. Topics include:
Both in-person and virtual guests must register in advance to participate in the Accuray meeting. Please RSVP here by September 25, 2025.
About Accuray
Accuray Incorporated (Nasdaq: ARAY) is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases – while making commonly treatable cases even easier – to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Madison, Wisconsin, with facilities worldwide.
Investor Contact
Aman Patel, CFA
Investor Relations, ICR Healthcare
+1 (443) 450-4191
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact
Beth Kaplan
Public Relations Director, Accuray
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$1.57 |
Daily Change: | -0.02 -1.26 |
Daily Volume: | 1,665,361 |
Market Cap: | US$176.910M |
August 13, 2025 May 05, 2025 April 30, 2025 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load